Why Novo Nordisk Stock Popped Today
Shares of Novo Nordisk (NYSE: NVO) rose more than 7% on Tuesday after the drugmaker received regulatory approval for its long-awaited GLP-1 pill in the U.S.
Image source: Novo Nordisk.
The U.S. Food and Drug Administration (FDA) approved the Danish healthcare leader's once-daily oral semaglutide treatment to reduce excess body weight and maintain weight reduction in adults.
Source Fool.com


